Cannabis Report
Home > Boards > US Listed > Biotechs >

Intellia Therapeutics Inc. (NTLA)

Add NTLA Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/8/2018 1:50:15 PM - Followers: 11 - Board type: Free - Posts Today: 0

Intellia Therapeutics, Inc. is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company's CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing. Its portfolio includes CRISPR/Cas9 platform technology, delivery technologies and nucleic acid modifications for human therapeutic use. The Company's CRISPR/Cas9 platform components include the guide ribonucleic acid (RNA) and the Cas9 nuclease (the genetic scissors). It has access to various delivery modalities specific to various in vivo and ex vivo approaches. The Company focuses on engineering ex vivo CRISPR/Cas9 cell therapies for chimeric antigen receptor T cell (CAR-T) and hematopoietic stem cell (HSC) applications. It also focuses on the use of in vivo Lipid Nanoparticle (LNP) delivery technology.
Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTLA News: CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding t... 09/10/2018 04:30:00 PM
NTLA News: Intellia Therapeutics to Present at September Healthcare Investor Conferences 08/27/2018 08:00:00 AM
NTLA News: Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome... 08/23/2018 04:01:00 PM
NTLA News: Intellia Therapeutics to Host Educational Briefing Webinar on Interference Proceedings Relating to CRISPR/Cas9 Genome Editing... 08/23/2018 08:30:00 AM
NTLA News: Initial Statement of Beneficial Ownership (3) 08/10/2018 04:45:54 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!